[Chinese consensus for the bispeific T cell engager in the treatment of B-cell acute lymphoblastic leukemia (2022)].
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):448-455. doi: 10.3760/cma.j.issn.0253-2727.2022.06.002.
Abstract
摘要
相似文献
1
[Chinese consensus for the bispeific T cell engager in the treatment of B-cell acute lymphoblastic leukemia (2022)].双特异性T细胞衔接器治疗B细胞急性淋巴细胞白血病中国专家共识（2022年）
Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):448-455. doi: 10.3760/cma.j.issn.0253-2727.2022.06.002.
2
[Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)].《双特异性T细胞衔接器治疗急性淋巴细胞白血病中国专家共识（2024年版）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):629-636. doi: 10.3760/cma.j.cn121090-20240528-00194.
3
Abnormal Lymphoid Cells in T-Cell Acute Lymphoblastic Leukemia/Lymphoma Resembling Burkitt Lymphoma Morphology.T细胞急性淋巴细胞白血病/淋巴瘤中形态类似伯基特淋巴瘤的异常淋巴细胞
Turk J Haematol. 2023 Aug 31;40(3):230-231. doi: 10.4274/tjh.galenos.2023.2023.0148. Epub 2023 Jun 20.
4
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.嵌合抗原受体 T 细胞治疗 B 细胞急性淋巴细胞白血病的临床经验。
Best Pract Res Clin Haematol. 2021 Sep;34(3):101305. doi: 10.1016/j.beha.2021.101305. Epub 2021 Aug 27.
5
Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.苔藓抑素激活 CAR T 细胞抗原非特异性杀伤（CTAK）和 CAR-TNK 样杀伤用于前体 B 细胞急性淋巴细胞白血病，同时阻止 Burkitt 淋巴瘤细胞系的细胞溶解。
Front Immunol. 2022 Feb 9;13:825364. doi: 10.3389/fimmu.2022.825364. eCollection 2022.
6
Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.Blinatumomab 治疗中国 Ph 阴性复发/难治性 B 细胞前体急性淋巴细胞白血病成人患者的疗效和安全性：一项多中心、开放标签、单臂中国注册研究。
Hematology. 2022 Dec;27(1):917-927. doi: 10.1080/16078454.2022.2111992.
7
A case of KMT2A-MLLT3 fusion-positive mature B-cell acute lymphoblastic leukemia.一例KMT2A-MLLT3融合阳性的成熟B细胞急性淋巴细胞白血病病例。
Pediatr Int. 2021 Jun;63(6):719-722. doi: 10.1111/ped.14477. Epub 2021 Apr 19.
8
Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.Blinatumomab 作为桥接治疗在儿童 B 细胞急性淋巴细胞白血病合并侵袭性真菌病中的应用。
Br J Haematol. 2022 Sep;198(5):887-892. doi: 10.1111/bjh.18314. Epub 2022 Jun 21.
9
10
Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.Blinatumomab 克服了小儿高危首诊复发 B 细胞前体急性淋巴细胞白血病中可测量残留病灶的不良预后影响。
Pediatr Blood Cancer. 2022 Aug;69(8):e29715. doi: 10.1002/pbc.29715. Epub 2022 Apr 28.
引用本文的文献
1
[Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)].《双特异性T细胞衔接器治疗急性淋巴细胞白血病中国专家共识（2024年版）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):629-636. doi: 10.3760/cma.j.cn121090-20240528-00194.
2
Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children.短疗程博纳吐单抗治疗儿童难治性/复发性前体B细胞急性淋巴细胞白血病
Front Pediatr. 2023 Aug 4;11:1187607. doi: 10.3389/fped.2023.1187607. eCollection 2023.
本文引用的文献
1
High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL.高肿瘤负荷对blinatumomab 治疗前的成人 B 细胞前体急性淋巴细胞白血病患者的结局有负面影响。GRAALL 的一项真实世界研究。
Haematologica. 2022 Sep 1;107(9):2072-2080. doi: 10.3324/haematol.2021.280078.
2
Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.成人复发/难治性B细胞前体急性淋巴细胞白血病患者在使用blinatumomab之前进行肿瘤减灭的真实世界多中心经验。
Front Oncol. 2022 Jan 6;11:804714. doi: 10.3389/fonc.2021.804714. eCollection 2021.
3
Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers.博纳吐单抗治疗复发/难治性B细胞前体急性淋巴细胞白血病儿童和青少年：意大利儿童血液学和肿瘤学协会（AIEOP）七个中心的一项真实世界多中心回顾性研究
Cancers (Basel). 2022 Jan 15;14(2):426. doi: 10.3390/cancers14020426.
4
Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study.在真实环境中使用blinatumomab 治疗急性淋巴细胞白血病的儿科患者：来自 NEUF 研究的结果。
Pediatr Blood Cancer. 2022 Apr;69(4):e29562. doi: 10.1002/pbc.29562. Epub 2022 Jan 19.
5
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.Blinatumomab 与化疗治疗高危初发 B 细胞急性淋巴细胞白血病患儿无事件生存的效果：一项随机临床试验。
JAMA. 2021 Mar 2;325(9):843-854. doi: 10.1001/jama.2021.0987.
6
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.Blinatumomab 巩固化疗后与化疗对初发 B 细胞急性淋巴细胞白血病儿童、青少年和年轻成人患者无病生存的影响：一项随机临床试验。
JAMA. 2021 Mar 2;325(9):833-842. doi: 10.1001/jama.2021.0669.
7
Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia.博纳吐单抗治疗高危复发B细胞急性淋巴细胞白血病儿童患者
JAMA. 2021 Mar 2;325(9):830-832. doi: 10.1001/jama.2021.1395.
8
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.达沙替尼联合博纳吐单抗治疗成人费城染色体阳性急性淋巴细胞白血病。
N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272.
9
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study.博纳吐单抗治疗复发/难治性急性淋巴细胞白血病儿童患者：扩展入组研究RIALTO试验结果
Blood Cancer J. 2020 Jul 24;10(7):77. doi: 10.1038/s41408-020-00342-x.
10
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.blinatumomab 治疗成人微小残留病 B 细胞前体急性淋巴细胞白血病的疗效。
Leuk Lymphoma. 2020 Nov;61(11):2665-2673. doi: 10.1080/10428194.2020.1780583. Epub 2020 Jul 3.
Zotero 插件